CA2389667A1 - Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors - Google Patents
Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors Download PDFInfo
- Publication number
- CA2389667A1 CA2389667A1 CA002389667A CA2389667A CA2389667A1 CA 2389667 A1 CA2389667 A1 CA 2389667A1 CA 002389667 A CA002389667 A CA 002389667A CA 2389667 A CA2389667 A CA 2389667A CA 2389667 A1 CA2389667 A1 CA 2389667A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- vector
- cell
- molecule
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013598 vector Substances 0.000 title claims abstract description 300
- 108700019146 Transgenes Proteins 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 421
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 210000003494 hepatocyte Anatomy 0.000 claims description 32
- 210000000130 stem cell Anatomy 0.000 claims description 28
- 230000035755 proliferation Effects 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 26
- 230000001105 regulatory effect Effects 0.000 claims description 25
- 102000011931 Nucleoproteins Human genes 0.000 claims description 23
- 108010061100 Nucleoproteins Proteins 0.000 claims description 23
- 230000006870 function Effects 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 238000004806 packaging method and process Methods 0.000 claims description 21
- 230000003612 virological effect Effects 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 19
- 230000004069 differentiation Effects 0.000 claims description 19
- 241001430294 unidentified retrovirus Species 0.000 claims description 19
- 108010017842 Telomerase Proteins 0.000 claims description 17
- 210000002889 endothelial cell Anatomy 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 17
- 210000002510 keratinocyte Anatomy 0.000 claims description 17
- 210000003098 myoblast Anatomy 0.000 claims description 16
- 230000032258 transport Effects 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 15
- 230000035897 transcription Effects 0.000 claims description 15
- 241000713666 Lentivirus Species 0.000 claims description 14
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 claims description 14
- 230000010354 integration Effects 0.000 claims description 13
- 230000012223 nuclear import Effects 0.000 claims description 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 12
- 101710149136 Protein Vpr Proteins 0.000 claims description 12
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 12
- 239000003623 enhancer Substances 0.000 claims description 12
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 11
- 108010061833 Integrases Proteins 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 11
- 101710128836 Large T antigen Proteins 0.000 claims description 10
- -1 NEF Proteins 0.000 claims description 10
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 10
- 210000004443 dendritic cell Anatomy 0.000 claims description 10
- 108010051219 Cre recombinase Proteins 0.000 claims description 9
- 210000002919 epithelial cell Anatomy 0.000 claims description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000001537 neural effect Effects 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 6
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 6
- 208000010094 Visna Diseases 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 230000001173 tumoral effect Effects 0.000 claims description 6
- 108060003393 Granulin Proteins 0.000 claims description 5
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 claims description 5
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000012239 gene modification Methods 0.000 claims description 4
- 230000005017 genetic modification Effects 0.000 claims description 4
- 235000013617 genetically modified food Nutrition 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 210000004180 plasmocyte Anatomy 0.000 claims description 4
- 108010070047 Notch Receptors Proteins 0.000 claims description 3
- 102000005650 Notch Receptors Human genes 0.000 claims description 3
- 108700020796 Oncogene Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 101150001535 SRC gene Proteins 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 210000003890 endocrine cell Anatomy 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 108091062157 Cis-regulatory element Proteins 0.000 claims description 2
- 108010002459 HIV Integrase Proteins 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 101710101493 Viral myc transforming protein Proteins 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 108010014186 ras Proteins Proteins 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000006490 viral transcription Effects 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 4
- 230000008569 process Effects 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 16
- 102100034349 Integrase Human genes 0.000 description 15
- 210000004940 nucleus Anatomy 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 241000713869 Moloney murine leukemia virus Species 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229960002963 ganciclovir Drugs 0.000 description 8
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 6
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 6
- 241000714474 Rous sarcoma virus Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000702191 Escherichia virus P1 Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000001964 muscle biopsy Methods 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- CNQAFFMNJIQYGX-DRZSPHRISA-N Ala-Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 CNQAFFMNJIQYGX-DRZSPHRISA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- SCQIQCWLOMOEFP-DCAQKATOSA-N Asp-Leu-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SCQIQCWLOMOEFP-DCAQKATOSA-N 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- UWKPRVKWEKEMSY-DCAQKATOSA-N Gln-Lys-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UWKPRVKWEKEMSY-DCAQKATOSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000005289 Neoplastic Cell Transformation Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- WNKZOJNKBOBRAY-UHFFFAOYSA-N cdba Chemical compound O=CC1=CC=CC=C1.O1C(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(O)C2O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC2C(O)C(O)C1OC2COC WNKZOJNKBOBRAY-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000026232 mitotic prophase Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 108700029760 synthetic LTSP Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99123498A EP1103615A1 (en) | 1999-11-25 | 1999-11-25 | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| EP99123498.0 | 1999-11-25 | ||
| PCT/EP2000/011723 WO2001038548A2 (en) | 1999-11-25 | 2000-11-24 | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2389667A1 true CA2389667A1 (en) | 2001-05-31 |
Family
ID=8239461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002389667A Abandoned CA2389667A1 (en) | 1999-11-25 | 2000-11-24 | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090142841A1 (enExample) |
| EP (2) | EP1103615A1 (enExample) |
| JP (1) | JP2003514565A (enExample) |
| AU (1) | AU2667901A (enExample) |
| CA (1) | CA2389667A1 (enExample) |
| WO (1) | WO2001038548A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006304392B2 (en) | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| JP2010521170A (ja) | 2007-03-13 | 2010-06-24 | ナショナル ジューイッシュ ヘルス | 抗体の生成方法 |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| KR101803099B1 (ko) | 2008-05-16 | 2017-11-30 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| ES2525411T3 (es) * | 2008-07-21 | 2014-12-22 | Taiga Biotechnologies, Inc. | Células anucleadas diferenciadas y método para preparar las mismas |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| JP2013511275A (ja) | 2009-11-18 | 2013-04-04 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 組織再生を誘導する方法 |
| JP5863338B2 (ja) * | 2011-08-25 | 2016-02-16 | 株式会社東芝 | プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット |
| WO2013057164A1 (en) | 2011-10-18 | 2013-04-25 | Sarl Endocells | Production of a human beta cell line from an early post natal pancreas |
| EP2877189B1 (en) | 2012-07-20 | 2021-01-06 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| WO2014109696A1 (en) * | 2013-01-10 | 2014-07-17 | Alf Grandien | Method for immortalization of b cells and uses thereof |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| CN103468746B (zh) * | 2013-09-28 | 2015-03-04 | 青岛麦迪赛斯生物科技有限公司 | 一种肿瘤细胞系的构建方法 |
| US11629337B2 (en) | 2016-05-11 | 2023-04-18 | Animal Cell Therapy—Act | Production of a canine beta cell line from an immature pancreas |
| EP4242298A2 (en) | 2016-12-02 | 2023-09-13 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US20210369788A1 (en) | 2017-11-08 | 2021-12-02 | Animal Cell Therapy - Act | Production of canine pancreatic islets from an immature pancreas |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
| CN111154807B (zh) * | 2020-01-17 | 2023-03-24 | 山东农业大学 | 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法 |
| WO2022066937A1 (en) * | 2020-09-23 | 2022-03-31 | Regents Of The University Of Minnesota | Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use |
| JPWO2022097716A1 (enExample) * | 2020-11-06 | 2022-05-12 | ||
| KR102572595B1 (ko) * | 2020-12-02 | 2023-08-31 | 충북대학교 산학협력단 | 불멸화 고양이줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
| KR102456805B1 (ko) * | 2020-12-02 | 2022-10-24 | 충북대학교 산학협력단 | 불멸화 개줄기세포 또는 이의 엑소좀풍부배양액을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
| CN112941033A (zh) * | 2021-03-11 | 2021-06-11 | 深圳市人民医院 | 永生化饲养层细胞株的构建方法、永生化饲养层细胞株及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686306A (en) * | 1992-05-13 | 1997-11-11 | Board Of Regents, The University Of Texas System | Methods and reagents for lengthening telomeres |
| US5919997A (en) * | 1993-11-18 | 1999-07-06 | Cold Spring Habor Labortary | Transgenic mice having modified cell-cycle regulation |
| US5729597A (en) * | 1995-05-16 | 1998-03-17 | At&T Corp | Service and information management system for a telecommunications network |
| US5629159A (en) * | 1995-06-07 | 1997-05-13 | California Institute Of Technology | Immortalization and disimmortalization of cells |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1998000537A1 (en) * | 1996-07-01 | 1998-01-08 | Universite De Sherbrooke | Composition and methods for modulating the length of telomeres |
| CA2265522A1 (en) * | 1996-09-17 | 1998-03-26 | The Salk Institute For Biological Studies | Retroviral vectors capable of transducing non-dividing cells |
| AU7332198A (en) * | 1997-03-06 | 1998-09-22 | Klaus Uberla | Lentivirus based vector and vector system |
| JP2001517433A (ja) * | 1997-09-24 | 2001-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非霊長類レンチウイルスベクターおよびパッケージングシステム |
| WO1999035243A2 (en) * | 1998-01-12 | 1999-07-15 | Cold Spring Harbor Laboratory | Extension of cellular lifespan, methods and reagents |
| US6365150B1 (en) * | 1998-05-13 | 2002-04-02 | Genetix Pharmaceuticals, Inc. | Lentiviral packaging cells |
-
1999
- 1999-11-25 EP EP99123498A patent/EP1103615A1/en not_active Withdrawn
-
2000
- 2000-11-24 JP JP2001539890A patent/JP2003514565A/ja active Pending
- 2000-11-24 CA CA002389667A patent/CA2389667A1/en not_active Abandoned
- 2000-11-24 AU AU26679/01A patent/AU2667901A/en not_active Abandoned
- 2000-11-24 EP EP00989880A patent/EP1244798A2/en not_active Withdrawn
- 2000-11-24 WO PCT/EP2000/011723 patent/WO2001038548A2/en not_active Ceased
-
2008
- 2008-08-28 US US12/231,088 patent/US20090142841A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003514565A (ja) | 2003-04-22 |
| EP1103615A1 (en) | 2001-05-30 |
| AU2667901A (en) | 2001-06-04 |
| US20090142841A1 (en) | 2009-06-04 |
| WO2001038548A2 (en) | 2001-05-31 |
| EP1244798A2 (en) | 2002-10-02 |
| WO2001038548A3 (en) | 2001-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090142841A1 (en) | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors | |
| Reiser et al. | Development of multigene and regulated lentivirus vectors | |
| US8652837B2 (en) | Method and means for producing high titer, safe, recombinant lentivirus vectors | |
| Salmon et al. | Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes | |
| Hamaguchi et al. | Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro | |
| Boris-Lawrie et al. | Recent advances in retrovirus vector technology | |
| KR102091957B1 (ko) | 레트로바이러스 생산을 위한 안정한 세포주 | |
| CA2328404C (en) | Novel lentiviral packaging cells | |
| US20220315950A1 (en) | Bio-production of lentiviral vectors | |
| KR20000049250A (ko) | 렌티바이러스 벡터 | |
| Sparacio et al. | Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors | |
| EP4144856A1 (en) | Production cell and packaging cell for retroviral vector and preparation method therefor | |
| CN110520535B (zh) | 用于逆转录病毒产生的稳定细胞系 | |
| Hennig et al. | HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA | |
| Mikkola et al. | Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells | |
| Santhosh et al. | A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo | |
| US20080124308A1 (en) | Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins | |
| Gropp et al. | Lentiviral vector–mediated gene delivery into human embryonic stem cells | |
| Painter et al. | Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post‐therapeutic deletion of tumorigenesis | |
| Molina et al. | Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector | |
| Trono et al. | Hanna Mikkola, Niels-Bjarne Woods, Marketa Sjögren | |
| US20060134137A1 (en) | Transduction vector based on modified HIV-2 | |
| Kafri | Gene Delivery by Lentivirus Vectors | |
| Hennig et al. | HEK293-based production platform for γ-retroviral (SIN-) vectors: application for safe and efficient transfer of COL7A1 cDNA | |
| Curran et al. | Recombinant feline immunodeficiency virus vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |